[HTML][HTML] RELAY, ramucirumab plus erlotinib (RAM+ ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and …
M Nishio, L Paz-Ares, M Reck, K Nakagawa… - Clinical Lung Cancer, 2023 - Elsevier
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …
Rational Application of First‐Line EGFR‐TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR‐Mutant Non‐Small‐Cell Lung Cancer: A Systematic …
JT Ma, YJ Guo, J Song, L Sun, SL Zhang… - BioMed Research …, 2021 - Wiley Online Library
Purpose. A meta‐analysis of randomized controlled trials (RCTs) was conducted to compare
the difference in efficacy and safety between epidermal growth factor receptor‐tyrosine …
the difference in efficacy and safety between epidermal growth factor receptor‐tyrosine …
[HTML][HTML] Present and future perspectives of anti-angiogenic therapy
E IO, ESH CLL - memoinoncology.com
The oral, triple angiokinase inhibitor nintedanib has been approved in the European Union
and other countries in combination with docetaxel for the treatment of advanced …
and other countries in combination with docetaxel for the treatment of advanced …
[PDF][PDF] 肺癌患者におけるEGFR 遺伝子変異検査の手引き
日本肺癌学会， 西野和美， 西尾和人， 畑中豊， 池田貞勝… - 2016 - haigan.gr.jp
第 1.0 版 2009 年 3 月 6 日第 1.7 版 2009 年 5 月 11 日第 2.0 版 2014 年 2 月 11 日第 2.1 版
2014 年 4 月 14 日第 3.0 版 2016 年 11 月 2 日第 3.05 版 2016 年 12 月 1 日第 4.0 版 2018 年 …
2014 年 4 月 14 日第 3.0 版 2016 年 11 月 2 日第 3.05 版 2016 年 12 月 1 日第 4.0 版 2018 年 …